Luigi Biasco

Critically assess the clinical implications of the EARLY TAVI and NOTION-3 trials with a focus on asymptomatic aortic stenosis and concomitant coronary artery disease. This session integrates recent evidence into patient-centered care pathways, offering case-based insights for optimizing timing and management strategies in TAVI patients.

Luigi Biasco provides his take on a sub-analysis of the Early TAVR trial about the early and delayed aortic valve replacement implant patients presented by Philippe Genereux at ACC.25 in Chicago.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

Luigi Biasco provides his take on the results of the EARLY TAVR trial, presented by Philippe Genereux at TCT 2024 in Washington.

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

This session will feature selected EuroPCR 2024 Clinical Case submissions focused on unusual cases of patent foramen ovale (PFO) closure. Attendees will have the opportunity to explore challenging cases, such as unexplained hypoxemia in an elderly man post-lung cancer lobectomy, a case of persistent dyspnea and...

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24

Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.

TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...

The study aim was to develop and validate a novel score for prediction of 1-year mortality and clinical outcomes through artificial intelligence (AI) application in patients undergoing M-TEER.

Discover the mitral late-breaking trials which were presented during PCR London Valves 2023: 

• One-year outcomes of transcatheter mitral repair from the CLASP IID Registry
• AltaValve transseptal programme update
• Mitral TEER in men and women from MitraSwiss registry: is equality achieved?
• Combined impact of mitral valve gradients and mitral regurgitation reduction...

Luigi Biasco interviews Suzanne V. Arnold about the results of the randomized TRILUMINATE pivotal trial which she presented during the TCT Congress 2023 in San Francisco

Thanks to the contribution of our team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science to be released at TCT 2023 - check out the list here!

What was new and hot in interventional cardiology at #ESCCongress 2023!

Luigi Biasco interviews Troels Højsgaard Jørgensen regarding the 10-year results of the NOTION trial which he presented at the ESC Congress 2023 in Amsterdam.

What can you learn about valve durability and life expectancy?

The results of PREDICT-LAA remain fascinating and point focus on a current topic such as the use of AI models in planning structural cardiac interventions.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology / World Heart Federation 2023 Scientific Sessions #ACC23 #WCCardio.

Pediatric patients requiring anticoagulation are a rare but extremely complex subgroup, with congenital (univentricular circulation, Fontan circulation, venous-to-systemic shunts) or acquired diseases (Kawasaki disease), which represents a therapeutic and logistic challenge.

Thanks to the contribution of a team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science released at TCT 2022 - check out the list here!

Mirvat Alasnag interviews Luigi Biasco, first author of the MitraSwiss Registry which was presented at the ESC Congress 2022 in Barcelona. Together, they discuss the enrolled population, the inclusion criteria, the design and outcomes of MitraSwiss, its comparison with other European registries and the restoration of...

Luigi Biasco interviews Scott Lim and Konstantinos P. Koulogiannis, Principal Investigators of CLASP IID.

The trial demonstrated safety and effectiveness of the PASCAL system and met non-inferiority endpoints, expanding transcatheter treatment options for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation.

Luigi provides us with the interventional cardiologist's point of view!

Currently, TAVR selection process is performed by matching the internal diameter of the surgically implanted bioprostheses to the external diameter of commercially available TAVR devices. Nonetheless, the impact of intrinsic design differences, such as supra vs intra-annular design,...

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2022 Scientific Sessions #ACC22.

Alessandro Sticchi and Luigi Biasco provide their take on the 1-year results of the CLASP TR study which were presented by Dr Adan Greenbaum, co-director of the Emory Structural Heart and Valve Center (Atlanta, GA) during the 2022 American College of Cardiology annual Congress held in Washington D.C.

The study by Zahr et al. reports the results of an interim analysis assessing procedural and clinical outcomes at 30-day in 15 patients treated with the newly developed Medtronic Intrepid 35-F trans-femoral transcatheter mitral valve replacement (TMVR) system.

An active surveillance programme was initiated by the Israeli Ministry of Health to ascertain the possible causal relationship between the vaccine and myocarditis and evaluate incidence, clinical relevance, and related outcomes.

Luigi Biasco reports the best of Dj Lakkireddy (Overland Park, USA)'s presentation of the AMULET IDE trial at the Monday, August 30 Hot Line session of the ESC Congress 2021.

Make sure you stay up to date with what's new and hot in interventional cardiology at this year's #ESCCongress!

The aim of this study was to determine the prognostic impact conferred by the presence of moderate AS on the outcomes of patients with HFrEF.